Celecoxib and Heterotopic Bone Formation After Total Hip Arthroplasty
Celecoxib and Heterotopic Bone Formation After Total Hip Arthroplasty
复制标题
DOI：
10.1016/j.arth.2013.06.039
复制
发表时间：
2014-02-01
影响因子：
3.5
通讯作者：
Rossi, Mark D.
中科院分区：
文献类型：
--
作者：
Lavernia, Carlos J.;Contreras, Juan S.;Rossi, Mark D.
我们评估了塞来昔布预防初次全髋关节置换术（THR）后异位骨化（HO）的有效性。我们研究了170例连续THR。63名患者在术后接受塞来昔布（200 mg，每日两次）治疗28天，84名患者未接受。在3、6和12个月时，非塞来昔布组患者的HO比塞来昔布组更常见（分别为P = 0.005、0.004和0.01）。在1年时，塞来昔布接受者中Brooker II级或III级较少。没有塞来昔布组患者发生HO Brooker IV级，而非塞来昔布组有2%发生。无患者因无菌性松动而停止治疗或进行翻修。短期塞来昔布止痛有助于预防初次THR后HO，可能是一种有用且安全的选择，不会干扰抗凝治疗。(C)2014 Elsevier Inc. All rights reserved.
We assessed the effectiveness of celecoxib in the prevention of heterotopic ossification (HO) following primary total hip replacement (THR). We studied 170 consecutive THRs. Sixty-three patients received celecoxib after surgery (200 mg twice/daily) for 28 days and 84 did not. HO was more common in non-celecoxib patients than in the celecoxib-group at 3, 6, and 12 months (P = 0.005, 0.004 and 0.01, respectively). At 1 year, fewer celecoxib recipients had Brooker classes II or III. None of the celecoxib patients developed HO Brooker class IV, while 2% in the non-celecoxib group did. No patient discontinued treatment or had revision for aseptic loosening. A short course of celecoxib for pain aids in the prevention of HO after primary THR, and could be a useful and safe option that does not interfere with anticoagulation. (C) 2014 Elsevier Inc. All rights reserved.